Mycophenolic acid


Thông tin kê toa tóm tắt
Chỉ định/Công dụng
Listed in Dosage.
Liều dùng/Hướng dẫn sử dụng
Adult : PO Prophylaxis of acute renal graft rejection As mycophenolate mofetil combined with other immunosuppressants: 1 g bid. As mycophenolic acid: 720 mg bid. Doses are given within 72 hours of transplantation. Prophylaxis of cardiac graft rejection As mycophenolate mofetil combined with other immunosuppressants: 1.5 g bid started within 5 days of transplantation. IV Prophylaxis of acute renal graft rejection As mycophenolate mofetil combined with other immunosuppressants: 1 g bid via IV infusion over 2 hours started within 24 hours of transplantation. Duration of therapy: Max 14 days. Convert to oral therapy as soon as tolerated. Prophylaxis of cardiac graft rejection As mycophenolate mofetil: 1.5 g bid via IV infusion over 2 hours starting within 5 days after transplantation, convert to oral administration as soon as tolerated. Prophylaxis of hepatic transplant rejection As mycophenolate mofetil: Initial: 1 g bid infused over 2 hours started within 24 hours of transplantation. Duration of treatment: 4 days up to Max 14 days. Then, convert to oral administration at 1.5 g bid as soon as tolerated.
Dosage Details
Intravenous
Prophylaxis of acute renal graft rejection
Adult: As mycophenolate mofetil: In combination with other immunosuppressants: 1 g bid via IV infusion over 2 hours started within 24 hours of transplantation. Duration of therapy: Max 14 days. Convert to oral therapy as soon as tolerated.

Intravenous
Prophylaxis of cardiac graft rejection
Adult: As mycophenolate mofetil: 1.5 g bid via IV infusion over 2 hours starting within 5 days after transplantation, convert to oral administration as soon as tolerated.

Intravenous
Prophylaxis of hepatic transplant rejection
Adult: As mycophenolate mofetil: Initially, 1 g bid via IV infusion over 2 hours started within 24 hours of transplantation. Duration of treatment: 4 days up to Max 14 days. Then, convert to oral administration at 1.5 g bid as soon as tolerated.

Oral
Prophylaxis of acute renal graft rejection
Adult: As mycophenolate mofetil: In combination with other immunosuppressants: 1 g bid started within 72 hours of transplantation. As mycophenolic acid: 720 mg bid started within 72 hours of transplantation.
Child: As mycophenolate mofetil: ≥3 months: 600 mg/m2 bid. Max: 2 g daily. BSA 1.25-1.5 m2: 750 mg bid; ≥1.5 m2: 1 g bid. As mycophenolic acid: ≥5 years: 400 mg/m2/dose bid. (Max: 1,400 mg daily). BSA 1.19-1.58 m2: 540 mg bid; >1.58 m2: 720 mg bid.

Oral
Prophylaxis of cardiac graft rejection
Adult: As mycophenolate mofetil: In combination with other immunosuppressants: 1.5 g bid started within 5 days of transplantation.
Renal Impairment
Oral:
Prophylaxis of acute renal graft rejection
Severe chronic renal impairment (GFR <25 mL/min/1.73 m2): Avoid >1 g bid of mycophenolate mofetil.

Intravenous:
Prophylaxis of acute renal graft rejection
Severe chronic renal impairment (GFR <25 mL/min/1.73 m2): Avoid >1 g bid of mycophenolate mofetil.
Hướng dẫn pha thuốc
IV: Reconstitute vial labelled as containing 500 mg with 14 mL of 5% dextrose injection; further dilute with 70 mL of 5% dextrose inj for IV infusion. Powder for oral suspension: Add a total of 94 mL of water to a bottle in order to provide a suspension containing 200 mg/mL. Shake the bottle after addition for approx 1 minute.
Chống chỉ định
Pregnancy, lactation. Rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) (e.g. Kelley-Seegmiller or Lesch-Nyhan syndrome).
Thận trọng
Patient with active serious gastrointestinal disease, active peptic ulcers. Renal impairment. Children. Avoid abrupt cessation of treatment. Mycophenolate mofetil and mycophenolate sodium are not interchangeable.
Phản ứng phụ
Significant: CNS depression, new or reactivation of viral infection, neutropenia, pure red cell aplasia, gastric or duodenal ulcers, gastrointestinal bleeding and/or perforation, myasthenia gravis (abrupt discontinuation of treatment).
Blood and lymphatic system disorders: Leucopenia, thrombocytopenia, anaemia, pancytopenia, leukocytosis.
Cardiac disorders: Tachycardia.
Gastrointestinal disorders: Vomiting, abdominal pain, diarrhoea, nausea, dysgeusia.
General disorders and administration site conditions: Oedema, pyrexia, chills, pain, malaise, asthenia.
Infections and infestations: Sepsis, gastrointestinal candidiasis, UTI, herpes simplex, herpes zoster.
Investigations: Increased hepatic enzymes.
Metabolism and nutrition disorders: Acidosis, gout, anorexia.
Musculoskeletal and connective tissue disorders: Arthralgia.
Neoplasms benign, malignant and unspecified: Skin cancer, benign skin neoplasm.
Nervous system disorders: Convulsion, hypertonia, tremor, somnolence, dizziness, headache, paraesthesia.
Psychiatric disorders: Agitation, confusional state, depression, anxiety, abnormal thinking, insomnia.
Respiratory, thoracic and mediastinal disorders: Pleural effusion, dyspnoea, cough.
Skin and subcutaneous tissue disorders: Skin hypertrophy, rash, acne, alopecia.
Vascular disorders: Hypertension, hypotension, vasodilation.
Potentially Fatal: Infections (e.g. progressive multifocal leukoencephalopathy, meningitis, infectious endocarditis), pulmonary fibrosis.
IV/Parenteral/PO: D
Thông tin tư vấn bệnh nhân
This drug may impair physical and mental ability, if affected, do not drive or operate machinery. Do not donate blood or blood products during treatment and for at least 6 months after the last dose.
MonitoringParameters
Monitor CBC, LFT, renal function. Perform pregnancy test prior to initiation of therapy; then after 8-10 days in women of child-bearing potential, followed by repeat test during therapy. Monitor for signs and symptoms of infection, neurological symptoms, lymphoma, pure red cell aplasia, and autoimmune haemolytic anaemia.
Tương tác
Mycophenolate mofetil may increase plasma concentration of aciclovir. Reduced absorption with antacids, polycarbophil calcium, sevelamer, colestyramine. Reduced MPA exposure with ciclosporin, antibiotics (e.g. aminoglycosides, cephalosporin, fluroquinolone, penicillins). Increased MPA exposure with isavuconazole, telmisartan. May reduce the efficacy of live attenuated vaccines.
Food Interaction
Food reduces MPA peak serum levels by 40% and 33% following mycophenolate mofetil and mycophenolate sodium administration, respectively.
Tác dụng
Description: Mycophenolic acid suppresses the proliferation of both T and B lymphocytes and antibody formation by inhibiting inosine monophosphate dehydrogenase, resulting in depletion of guanosine nucleotide which is necessary for de novo purine synthesis in lymphocytes.
Pharmacokinetics:
Absorption: Mycophenolate mofetil/mycophenolate Na: Rapidly and extensively absorbed from the gastrointestinal tract.
Distribution: Plasma protein binding: MPA: 97%.
Metabolism: Mycophenolate is metabolised pre-systemically into active mycophenolic acid (MPA), which undergoes enterohepatic recirculation. MPA is further metabolised via glucuronidation to inactive mycophenolic acid glucuronide.
Excretion: Mycophenolate: Via urine (as glucuronide and negligible amount of MPA); faeces (6%). Half-life of MPA: 17.9 hours (as oral mycophenolate mofetil); 16.6 hours (as IV mycophenolate mofetil); 12 hours (as mycophenolate Na).
Đặc tính

Chemical Structure Image
Mycophenolic acid_01

Source: National Center for Biotechnology Information. PubChem Database. Mycophenolic acid, CID=446541, https://pubchem.ncbi.nlm.nih.gov/compound/446541 (accessed on June 25, 2020)

Bảo quản
Inj: Store at 25°C. Cap/Tab/Susp: Store at 25°C. Protect from light and moisture. Reconstituted oral suspension: Store between 2-8°C. Do not freeze.
Phân loại MIMS
Phân loại ATC
L04AA06 - mycophenolic acid ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.
References
Anon. Mycophenolate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/06/2020.

Buckingham R (ed). Mycophenolate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/06/2020.

Cellcept Tablet, Film Coated, Capsule, Oral Suspension, Injection (Genentech, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 09/06/2020.

Joint Formulary Committee. Mycophenolate Mofetil. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/06/2020.

Mycophenolate Mofetil 250 m Hard Capsule (Accord Healthcare Limited). MHRA. https://products.mhra.gov.uk/. Accessed 09/06/2020.

Myfortic 180, 360 mg Gastro-Resistant Tablets (Novartis Corporation [M] Sdn. Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my/. Accessed 09/06/2020.

Myfortic Tablet, Delayed Release (Novartis Pharmaceuticals Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 14/06/2020.

Roche Products (New Zealand) Limited. Cellcept 250 mg Hard Capsules, 500 mg Film-Coated Tablets, 500 mg Powder for Infusion, 200 mg/mL Powder for Oral Suspension data sheet 15 August 2018. Medsafe. http://www.medsafe.govt.nz/. Accessed 09/06/2020.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Mycophenolic acid từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Kupcept
  • Mycophenolate mofetil Roxane
  • Mycophenolate mofetil TEVA
  • Myfortic
  • Mylaen
  • Renocell
  • Transfonex
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in